M R Mirza

Dostarlimab and niraparib in primary gevorderd ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology · 1 december 2025

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall surv...

Annals of oncology : official journal of the European Society for Medical Oncology · 1 november 2024

OS met dostarlimab plus carboplatine-paclitaxel bij endometriumcarcinoom: RUBY OS

Annals of oncology : official journal of the European Society for Medical Oncology · 1 augustus 2024

Immunotherapie plus eerstelijns bij gevorderd endometriumcarcinoom: overzicht

Annals of oncology : official journal of the European Society for Medical Oncology · 1 mei 2024

Endometriumcarcinoom: ESMO 2022 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 1 september 2022

Niraparib-onderhoud bij platinagevoelig recidief ovariumcarcinoom: individuele startdosis PRIMA subanalyse

Annals of oncology : official journal of the European Society for Medical Oncology · 1 april 2021

Veiligheid en dosismodificatie bij niraparib: praktische aanbevelingen

Annals of oncology : official journal of the European Society for Medical Oncology · 1 augustus 2018

Bevacizumab met of na chemotherapie bij platinaresistent recidief ovariumcarcinoom: AURELIA exploratieve analyses

Annals of oncology : official journal of the European Society for Medical Oncology · 1 augustus 2017

Slechte concordantie tussen CA-125 en RECIST bij ziekteprogressie van platinaresistent ovariumcarcinoom

Annals of oncology : official journal of the European Society for Medical Oncology · 1 augustus 2016

Publicaties op Oncologisch.com